long term effects of retatrutide Side Research Lilly's retatrutide shows 28% weight

J Endocr Soc 5(9):bvab118 Doggrell SA (2023) Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist, a step forward in the treatment of diabetes and obesity

Niwa, T

Some patients experience reduced appetite suppression over time, which is sometimes called tolerance, though true resistance is rare

These medications mimic the action of a hormone called glucagon-like peptide-1 (GLP-1), which is naturally released after eating to regulate blood sugar and control appetite

Genetic variants in the GLP-1 receptor, differences in gut microbiome composition, and carnitine metabolism may all play a role

Antioxidants (Basel)